KR101005367B1 - 발사르탄 또는 그의 대사산물의 혈소판 응집 억제 용도 - Google Patents

발사르탄 또는 그의 대사산물의 혈소판 응집 억제 용도 Download PDF

Info

Publication number
KR101005367B1
KR101005367B1 KR1020047018282A KR20047018282A KR101005367B1 KR 101005367 B1 KR101005367 B1 KR 101005367B1 KR 1020047018282 A KR1020047018282 A KR 1020047018282A KR 20047018282 A KR20047018282 A KR 20047018282A KR 101005367 B1 KR101005367 B1 KR 101005367B1
Authority
KR
South Korea
Prior art keywords
valsartan
delete delete
platelet aggregation
methyl
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047018282A
Other languages
English (en)
Korean (ko)
Other versions
KR20050000532A (ko
Inventor
알렉스 말리닌
빅터 엘. 서렙루안니
랜디 리. 웹
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29423705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101005367(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20050000532A publication Critical patent/KR20050000532A/ko
Application granted granted Critical
Publication of KR101005367B1 publication Critical patent/KR101005367B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020047018282A 2002-05-14 2003-05-13 발사르탄 또는 그의 대사산물의 혈소판 응집 억제 용도 Expired - Fee Related KR101005367B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38037302P 2002-05-14 2002-05-14
US60/380,373 2002-05-14
US39501402P 2002-07-11 2002-07-11
US60/395,014 2002-07-11
PCT/EP2003/004997 WO2003094915A1 (en) 2002-05-14 2003-05-13 Use of valsartan ot its metabolite to inhibit platelet aggregation

Publications (2)

Publication Number Publication Date
KR20050000532A KR20050000532A (ko) 2005-01-05
KR101005367B1 true KR101005367B1 (ko) 2010-12-30

Family

ID=29423705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047018282A Expired - Fee Related KR101005367B1 (ko) 2002-05-14 2003-05-13 발사르탄 또는 그의 대사산물의 혈소판 응집 억제 용도

Country Status (22)

Country Link
US (2) US20050197372A1 (https=)
EP (1) EP1505965B1 (https=)
JP (1) JP4467427B2 (https=)
KR (1) KR101005367B1 (https=)
CN (1) CN100408035C (https=)
AT (1) ATE334677T1 (https=)
AU (1) AU2003267447B8 (https=)
BR (1) BR0310018A (https=)
CA (1) CA2482541A1 (https=)
CY (1) CY1105638T1 (https=)
DE (1) DE60307265T2 (https=)
DK (1) DK1505965T3 (https=)
ES (1) ES2268403T3 (https=)
IL (2) IL164774A0 (https=)
MX (1) MXPA04011282A (https=)
NO (1) NO20045245L (https=)
NZ (1) NZ536295A (https=)
PL (1) PL371728A1 (https=)
PT (1) PT1505965E (https=)
RU (1) RU2334512C2 (https=)
TW (1) TWI299663B (https=)
WO (1) WO2003094915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
US10478404B2 (en) 2014-01-24 2019-11-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Materials, methods and devices for altering cell reactivity
CN110078640B (zh) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法
CN111643557B (zh) * 2020-05-26 2022-02-22 四川省骨科医院 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312198T1 (de) * 1993-04-05 2005-12-15 Univ Utah Res Found Diagnose und behandlung von supravalvular aortic stenosis
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
CA2379666C (en) * 1999-07-21 2009-10-13 Takeda Chemical Industries, Ltd. Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
AU2001267404A1 (en) * 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of cardiovascular pharmacology, 2000, 35(6), pp. 906-913
Journal of hypertension, 1999, 17(3), pp. 447-452
Xenobiotica 1997, 27(1), pp. 59-71

Also Published As

Publication number Publication date
AU2003267447A1 (en) 2003-11-11
KR20050000532A (ko) 2005-01-05
JP4467427B2 (ja) 2010-05-26
ATE334677T1 (de) 2006-08-15
DE60307265T2 (de) 2007-07-19
CN1652774A (zh) 2005-08-10
HK1074395A1 (en) 2005-11-11
PL371728A1 (en) 2005-06-27
CY1105638T1 (el) 2010-12-22
TW200410686A (en) 2004-07-01
AU2003267447B8 (en) 2009-08-06
NZ536295A (en) 2006-12-22
US20100048654A1 (en) 2010-02-25
JP2005529913A (ja) 2005-10-06
PT1505965E (pt) 2006-11-30
MXPA04011282A (es) 2005-01-25
AU2003267447B2 (en) 2006-11-02
WO2003094915A1 (en) 2003-11-20
BR0310018A (pt) 2005-02-15
CA2482541A1 (en) 2003-11-20
IL164774A0 (en) 2005-12-18
DK1505965T3 (da) 2006-11-13
EP1505965A1 (en) 2005-02-16
RU2334512C2 (ru) 2008-09-27
RU2004136583A (ru) 2005-09-10
IL164774A (en) 2010-04-29
US20050197372A1 (en) 2005-09-08
ES2268403T3 (es) 2007-03-16
DE60307265D1 (de) 2006-09-14
CN100408035C (zh) 2008-08-06
TWI299663B (en) 2008-08-11
EP1505965B1 (en) 2006-08-02
NO20045245L (no) 2004-11-30

Similar Documents

Publication Publication Date Title
US20240366570A1 (en) Method for treating inflammatory disorders
US20100048654A1 (en) Use of valsartan or its metabolite to in hibit platelet aggregation
JP6980767B2 (ja) ニコチニルアルコールエーテル誘導体、調製及び医薬組成物及び使用
KR20200118103A (ko) Anca 관련 혈관염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
JP2020507610A (ja) 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
WO2022271604A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
JP2006515877A (ja) 心臓血管、心肺、肺又は腎疾患の予防又は治療のための医薬併用剤
CN109923101B (zh) 环状化合物
WO2004054616A1 (ja) ケモカイン受容体の強結合部位に結合するアンタゴニストおよびアゴニスト
WO2005110386A2 (en) Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers
HK1074395B (en) Use of the metabolite of valsartan to inhibit platelet aggregation
WO2026058000A2 (en) Methods
US20230174671A1 (en) Compositions and methods for treating viral infections
HK1192712A (en) Combination therapy
HK1192712B (en) Combination therapy

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20131225

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20131225

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000